AbbVie Replaces Pfizer On Goldman’s Conviction Buy List

As far as Goldman Sachs is concerned, Pfizer (PFE) is out and AbbVie (ABBV) is in. Analyst Jami Rubin and her team removed Pfizer from the firm’s much touted Conviction Buy list on Tuesday, and replaced it with AbbVie. Now don’t panic. Goldman isn’t downgrading Pfizer. Rubin maintained her Buy rating and raised her 12-month [...]